3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
2
Unknown
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Thyroid Neoplasms
2
Neoplasms
2
Melanoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Hairy Cell
1
Leukemia
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Hepatoblastoma
1
Glioma
1
Ependymoma
1
Craniopharyngioma
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
85
pembrolizumab
78
Pemetrexed
68
Cisplatin
56
Paclitaxel
45
osimertinib
41
Nivolumab
40
durvalumab
37
Docetaxel
33
atezolizumab
20
Gemcitabine
18
Radiotherapy
17
Radiosurgery
16
amivantamab
15
Ipilimumab
15
130-nm albumin-bound paclitaxel
14
Taxes
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
12
Crizotinib
11
lazertinib
9
Radiation
9
Immunoglobulin G
9
Drug Therapy
9
Disulfides
9
Bevacizumab
9
tislelizumab
8
cemiplimab
8
alectinib
8
Erlotinib Hydrochloride
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Non-Small-Cell Lung
×
Vemurafenib
×
Clear all
NCT03178552
2026-06-05
B-FAST
Hoffmann-La Roche
Phase 2/3
Active not recruiting
1,000 enrolled